Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Long-term results of a European organization for research and treatment of cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone

被引:49
作者
Kurth, K
Tunn, U
Ay, R
Schroder, FH
PavoneMacaluso, M
Debruyne, F
TenKate, F
DePauw, M
Sylvester, R
Essed, E
Caubergh, RV
Hoekstra, JW
deVoogt, HJ
Newling, DWW
deReijke, TM
Mensink, HJA
Groen, JM
Jakse, G
Leisinger, HJ
Richards, B
Adib, RA
Robinson, M
Denis, L
Bouffioux, C
Schulman, C
Carpentier, PJ
机构
[1] ERASMUS UNIV ROTTERDAM, ROTTERDAM, NETHERLANDS
[2] UNIV NIJMEGEN, NIJMEGEN, NETHERLANDS
[3] RUHR UNIV BOCHUM, BOCHUM, GERMANY
[4] CITY HOSP, WEIDEN OBERPFALZ, GERMANY
[5] UNIV CLIN PALERMO, PALERMO, ITALY
[6] EUROPEAN ORG RES TREATMENT CANC, CTR DATA, BRUSSELS, BELGIUM
[7] BERGWEGZIEKENHUIS ROTTERDAM, IJSELLANDZIEKENHUIS, ROTTERDAM, NETHERLANDS
[8] BLEULANDZIEKENHUIS, GOUDA, NETHERLANDS
[9] BOSCH MEDICTR, DEN BOSCH, NETHERLANDS
[10] FREE UNIV AMSTERDAM, NL-1081 HV AMSTERDAM, NETHERLANDS
[11] UNIV CLIN GRONINGEN, GRONINGEN, NETHERLANDS
[12] MARIA STICHTING, HAARLEM, NETHERLANDS
[13] RHEIN WESTFAL TH AACHEN, AACHEN, GERMANY
[14] CHU VAUDOIS, LAUSANNE, SWITZERLAND
[15] YORK DIST GEN HOSP, YORK, N YORKSHIRE, ENGLAND
[16] PINDERFIELDS GEN HOSP, WAKEFIELDS, YORKS, ENGLAND
[17] NORMANTON & DIST HOSP, LEEDS, W YORKSHIRE, ENGLAND
[18] MIDDELHEIMZIEKENHUIS ANTWERP, ANTWERP, BELGIUM
[19] HOP BAVIERE, LIEGE, BELGIUM
[20] UNIV BRUSSELS CLIN, ERASME HOSP, BRUSSELS, BELGIUM
关键词
bladder; bladder neoplasms; carcinoma; transitional cell; doxorubicin; drug therapy;
D O I
10.1016/S0022-5347(01)64484-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We compared the efficacy of transurethral resection alone or transurethral resection followed by bladder instillations of doxorubicin or ethoglucid for 1 year in patients with superficial bladder carcinoma, and followed them long term for the incidence of progression to muscle invasion. Materials and Methods: A total of 443 patients with superficial transitional cell carcinoma of the bladder was randomized. After randomization of 206 patients the control arm was closed to patient entry based on the results of an interim analysis showing a significant difference in favor of those receiving adjuvant chemotherapy. Results: Final analysis of treatment results for recurrence included 432 patients at a median followup of 3.4 years for time to first recurrence, 5 years for analysis of time to invasion (Category T2 disease or worse) and 10.7 years for duration of survival. Time to first recurrence was significantly prolonged by both drugs compared to transurethral resection alone (doxorubicin versus transurethral resection alone p < 0.001 and ethoglucid versus control p < 0.001). Recurrence rate per year was 0.30 for both adjuvant treatment arms and 0.68 for the resection only group. Progression to muscle invasion was rare (15.1% of cases) and not apparently different in the 3 treatment arms. Of the 423 patients death from any cause in 199 and from malignant disease in 59 was not correlated with treatment. However, there was a strong correlation between death from malignant disease, and T category and tumor grade. Conclusions: In regard to time to first recurrence and recurrence rate per year this study indicates that adjuvant chemotherapy with doxorubicin and ethoglucid using the indicated schedule is superior to transurethral resection alone. However, progression in stage or survival was not influenced by the treatment regimen.
引用
收藏
页码:378 / 384
页数:7
相关论文
共 16 条
[1]  
[Anonymous], J AM STAT ASSOC
[2]   ADJUVANT CHEMOTHERAPY OF RECURRENT SUPERFICIAL TRANSITIONAL CELL-CARCINOMA - RESULTS OF A EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER RANDOMIZED TRIAL COMPARING INTRAVESICAL INSTILLATION OF THIOTEPA, DOXORUBICIN AND CISPLATIN [J].
BOUFFIOUX, C ;
DENIS, L ;
OOSTERLINCK, W ;
VIGGIANO, G ;
VERGISON, B ;
KEUPPENS, F ;
DEPAUW, M ;
SYLVESTER, R ;
CHEUVART, B .
JOURNAL OF UROLOGY, 1992, 148 (02) :297-301
[3]   DOES INTRAVESICAL CHEMOTHERAPY PREVENT INVASIVE BLADDER-CANCER [J].
GREEN, DF ;
ROBINSON, MRG ;
GLASHAN, R ;
NEWLING, D ;
DALESIO, O ;
SMITH, PH .
JOURNAL OF UROLOGY, 1984, 131 (01) :33-35
[4]  
HULAND H, 1983, EUR UROL, V9, P84
[5]   COMPARISON OF DIFFERENT SCHEDULES OF CYTOSTATIC INTRAVESICAL INSTILLATIONS IN PATIENTS WITH SUPERFICIAL BLADDER-CARCINOMA - FINAL EVALUATION OF A PROSPECTIVE MULTICENTER STUDY WITH 419 PATIENTS [J].
HULAND, H ;
KLOPPEL, G ;
FEDDERSEN, I ;
OTTO, U ;
BRACHMANN, W ;
HUBMANN, H ;
KAUFMANN, J ;
KNIPPER, W ;
LANTZIUSBENINGA, F ;
HULAND, E .
JOURNAL OF UROLOGY, 1990, 144 (01) :68-72
[6]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[7]   THE USE OF INTRAVESICAL THIO-TEPA IN THE MANAGEMENT OF NON-INVASIVE CARCINOMA OF THE BLADDER [J].
KOONTZ, WW ;
PROUT, GR ;
SMITH, W ;
FRABLE, WJ ;
MINNIS, JE .
JOURNAL OF UROLOGY, 1981, 125 (03) :307-312
[8]   FACTORS AFFECTING RECURRENCE AND PROGRESSION IN SUPERFICIAL BLADDER-TUMORS [J].
KURTH, KH ;
DENIS, L ;
BOUFFIOUX, C ;
SYLVESTER, R ;
DEBRUYNE, FMJ ;
PAVONEMACALUSO, M ;
OOSTERLINCK, W .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (11) :1840-1846
[9]   ADJUVANT CHEMOTHERAPY OF SUPERFICIAL TRANSITIONAL CELL BLADDER-CARCINOMA - PRELIMINARY-RESULTS OF A EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER RANDOMIZED TRIAL COMPARING DOXORUBICIN HYDROCHLORIDE, ETHOGLUCID AND TRANS-URETHRAL RESECTION ALONE-R [J].
KURTH, KH ;
SCHRODER, FH ;
TUNN, U ;
AY, R ;
PAVONEMACALUSO, M ;
DEBRUYNE, F ;
DEPAUW, M ;
DALESIO, O ;
TENKATE, F .
JOURNAL OF UROLOGY, 1984, 132 (02) :258-262
[10]  
NIIJIMA T, 1983, CANC CHEMOTHER S, V2, P579